Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancer

Elisabetta Munzone • 11 Sep 2022
ESMO 2022
Breast Cancer Capecitabine Cyclophosphamide Paclitaxel Vinorelbine
METEORA-II

Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses the trial design of the Phase II randomized, multi-center METEORA-II trial (NCT02954055), which compared metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) to weekly paclitaxel in patients with ER+/HER2- metastatic breast cancer. 140 patients, who were pretreated with either chemotherapy or endocrine therapy, were randomized to receive either weekly paclitaxel or metronomic VEX therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Elisabetta Munzone

Axillary management for breast cancer in the post-neoadjuvant setting
1:56
Axillary management for breast cancer in the post-neoadjuvant setting
Elisabetta Munzone • 16 May 2024
PREcoopERA: giredestrant versus anastrozole in ER+/HER2- early breast cancer
1:44
PREcoopERA: giredestrant versus anastrozole in ER+/HER2- early breast cancer
Elisabetta Munzone • 16 May 2024
Unanswered questions in the METEORA-II trial
0:48
Unanswered questions in the METEORA-II trial
Elisabetta Munzone • 11 Sep 2022
Advantages of metronomic chemotherapy in ER+/HER2- metastatic breast cancer
1:21
Advantages of metronomic chemotherapy in ER+/HER2- metastatic breast cancer
Elisabetta Munzone • 11 Sep 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals